BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9288126)

  • 41. Anti-CD3 treatment facilitates engraftment of full H-2-disparate donor bone marrow cells and subsequent skin allograft tolerance.
    de Vries-van Der Zwan A; Besseling AC; Kievits F; van Twuyver E; de Waal LP
    Transplantation; 1994 Sep; 58(5):610-7. PubMed ID: 7522366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions.
    Taylor PA; Lees CJ; Waldmann H; Noelle RJ; Blazar BR
    Blood; 2001 Jul; 98(2):467-74. PubMed ID: 11435318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of alphabeta- and gammadelta-T cells in allogenic donor marrow on engraftment, chimerism, and graft-versus-host disease.
    Huang Y; Cramer DE; Ray MB; Chilton PM; Que X; Ildstad ST
    Transplantation; 2001 Dec; 72(12):1907-14. PubMed ID: 11773887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2004 Nov; 32(11):1110-7. PubMed ID: 15539090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning.
    Graca L; Daley S; Fairchild PJ; Cobbold SP; Waldmann H
    BMC Immunol; 2006 Apr; 7():9. PubMed ID: 16638128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mixed allogeneic reconstitution (A+B----A) to induce donor-specific transplantation tolerance. Permanent acceptance of a simultaneous donor skin graft.
    Ildstad ST; Wren SM; Oh E; Hronakes ML
    Transplantation; 1991 Jun; 51(6):1262-7. PubMed ID: 1828637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD8 T cell of donor splenocyte mixed with bone marrow cells is more effective than CD4 T cell for induction of donor-specific tolerance in sublethally irradiated mice.
    Yoshida A; Narumi S; Hashimoto N; Itabashi Y; Hakamada K; Sasaki M
    Transplant Proc; 2004 Oct; 36(8):2418-22. PubMed ID: 15561266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Production of donor T cells is critical for induction of donor-specific tolerance and maintenance of chimerism.
    Xu H; Chilton PM; Huang Y; Schanie CL; Ildstad ST
    J Immunol; 2004 Feb; 172(3):1463-71. PubMed ID: 14734723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo.
    Johnson BD; Truitt RL
    Transplantation; 1992 Jul; 54(1):104-12. PubMed ID: 1631918
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A minimal conditioning approach to achieve stable multilineage mouse plus rat chimerism.
    Abou el-Ezz AY; Boggs SS; Johnson PC; Li H; Patrene KD; Itskowitz MS; Kaufman CL; Ildstad ST
    Transpl Immunol; 1995 Jun; 3(2):98-106. PubMed ID: 7582911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts.
    Colson YL; Zadach K; Nalesnik M; Ildstad ST
    Transplantation; 1995 Nov; 60(9):971-80. PubMed ID: 7491703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen.
    Sharabi Y; Sachs DH
    J Exp Med; 1989 Feb; 169(2):493-502. PubMed ID: 2562984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
    Soderling CC; Song CW; Blazar BR; Vallera DA
    J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms.
    Forman D; Welsh RM; Markees TG; Woda BA; Mordes JP; Rossini AA; Greiner DL
    J Immunol; 2002 Jun; 168(12):6047-56. PubMed ID: 12055213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tolerance induction through megadose bone marrow transplantation with two-signal blockade.
    Lee EN; Lee J; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Kwon CH; Joh JW; Kim SJ
    J Surg Res; 2006 Jan; 130(1):102-9. PubMed ID: 16183077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs.
    Down JD; Ploemacher RE
    Exp Hematol; 1993 Jul; 21(7):913-21. PubMed ID: 8100536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts.
    Gammie JS; Li S; Zeevi A; Demetris AJ; Ildstad ST; Pham SM
    Circulation; 1998 Nov; 98(19 Suppl):II163-8; discussion II168-9. PubMed ID: 9852899
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade.
    Foster RD; Pham S; Li S; Aitouche A
    Transplantation; 2003 Sep; 76(6):988-94. PubMed ID: 14508367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.